Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Jefferies Financial Group dropped their FY2020 earnings estimates for shares of Regeneron Pharmaceuticals in a report released on Wednesday, April 17th. Jefferies Financial Group analyst B. Amin now expects that the biopharmaceutical company will post earnings per share of $19.81 for the year, down from their prior estimate of $20.78. Jefferies Financial Group has a “Hold” rating and a $343.00 price target on the stock. Jefferies Financial Group also issued estimates for Regeneron Pharmaceuticals’ FY2021 earnings at $20.13 EPS, FY2022 earnings at $19.86 EPS and FY2023 earnings at $20.12 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same quarter in the prior year, the company earned $5.23 EPS. Regeneron Pharmaceuticals’s revenue was up 21.9% on a year-over-year basis.

Several other equities analysts have also recently commented on the stock. BidaskClub cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Piper Jaffray Companies raised their price objective on shares of Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a research note on Tuesday, February 26th. Guggenheim lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $466.00 to $425.00 in a research note on Friday, February 22nd. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Finally, Oppenheimer lifted their price target on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research report on Thursday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $413.94.

Shares of REGN stock traded down $9.63 during trading hours on Friday, hitting $333.34. 1,860,815 shares of the company were exchanged, compared to its average volume of 744,359. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. Regeneron Pharmaceuticals has a one year low of $281.89 and a one year high of $442.00. The stock has a market capitalization of $36.43 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 1.46 and a beta of 1.18.

Several institutional investors have recently modified their holdings of REGN. Whittier Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 45 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at $29,000. Rehmann Capital Advisory Group boosted its holdings in Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 68 shares during the period. AdvisorNet Financial Inc boosted its holdings in Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 52 shares during the period. Finally, Captrust Financial Advisors purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 66.97% of the company’s stock.

In other news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 12.42% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Book Value Per Share – BVPS

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.